当前位置: 首页 > 期刊 > 《健康必读(上旬刊)》 > 20185
编号:13587382
心力衰竭尿标本相关生物标志物研究现状(5)
http://www.100md.com 2018年5月1日 《健康必读(上旬刊)》 20185
     [25]ManzanoFernandez S, LJanuzzi J, Garcia M B, etal. Comparative Prognostic Value of Plasma and Urinary N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Acute Destabilized Heart Failure[J]. Rev Esp Cardiol, 2011, 64(5):365-372.

    [26]Mehrnoush Toufan, Hossein Namdar, Mohsen Abbasnezhad. Diagnostic Values of Plasma, Fresh and Frozen Urine NT-proBNP in Heart Failure Patients[J]. Cardiovasc Thorac Res, 2014, 6(2):111-115.

    [27]王淑婵, 冯书锐. UMA、BNP、hs CRP及UACR联合检测对慢性心衰患者的诊治及预后评估的价值[J]. 海南医学, 2016, 27(15).

    [28]Hahn R G, Jaarsma T, Nana Waldréus & Gerard C. M. Linssen. Urine measurement indicates the plasma brain natriuretic peptide concentration during optimization of heart failure treatment[J]. Scandinavian Journal Of Clinical &Laboratory Investigation,2016, 2(76):112-117.

    [29]吳君, 李永旺, 钟雪焱, 等. 检测慢性心力衰竭患者尿液肾损伤分子一1及血清胱抑素C的临床意义[J]. 中国心血管病研究, 2015, 13(11).

    [30]Stevens PE, Levin A. Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: Synopsis of the kidney disease[J]. Ann Intern Med , 2013(158):825-830.

    [31]Schiffmann R, MD; Sabrina Forni, MS; Caren Swift. Risk of Death in Heart Disease is Associated With Elevated Urinary Globotriaosylceramide[J]. Am Heart Assoc, 2014(3)., 百拇医药(阿迪拉?帕力哈提 穆叶赛?尼加提)
上一页1 2 3 4 5